Clinical trials: Operable Breast Neoplasms
Ovarian Carcinoma, Breast Carcinoma
Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma
GYNECO-IMM\&Co is a prospective clinical and biological cohort ; this study aims to identify immune surveillance and escape mechanisms and also predictive biomarkers for survival patients who suffer from ovarian and breast…
- Trial name
- GYNECO-IMM&CO (NCT04562623)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Centre Leon Berard
Breast Cancer, Luminal B
Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients
Observational study to evaluate the effect of physical exercise prior to surgery and adjuvant systemic treatment in women with newly diagnosed operable hormone receptor(HR)-positive, human epidermal growth factor receptor 2…
- Trial name
- EFIK (NCT03860740)
- Testing
- Exercise, Stretching
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Spanish Breast Cancer Research Group
HER-2 Positive Breast Cancer
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2…
- Trial name
- NCT01340430
- Testing
- Trastuzumab
- Where
- 6 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Lucia Del Mastro,MD
Breast Cancer, HER2-positive Breast Cancer
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
In 2020, the incidence of breast cancer surpassed that of lung cancer for the first time, becoming the number one cancer in the world. HER2 is an important prognostic indicator and therapeutic target for breast cancer.
- Trial name
- NCT05474690
- Testing
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
- Where
- China
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002460
- Testing
- goserelin acetate, tamoxifen citrate, ablative endocrine surgery
- Where
- 34 sites in Belgium, United Kingdom
- Sponsor
- Cancer Research UK
Breast Cancer
Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, docetaxel, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00801411
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 2 sites in Singapore
- Volunteers
- 318 people
- Sponsor
- National Cancer Centre, Singapore
Breast Neoplasms
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Primary objective: Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin…
- Trial name
- NCT00021255
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 42 sites in United States, Argentina and 40 more
- Volunteers
- 3,222 people
- Sponsor
- Sanofi
HER2-positive Breast Cancer
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
The primary objective of this study is to determine the efficacy of metformin as a repurposed agent in human epidermal growth factor receptor 2 (HER2) positive breast cancer when added to standard neo-adjuvant chemotherapy.
- Trial name
- HERMET (NCT03238495)
- Testing
- Taxotere, Carboplatin, Herceptin + Pertuzumab, Metformin
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Qamar Khan
Breast Cancer
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer.
- Trial name
- NCT00546156
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ian E. Krop, MD, PhD
HER-2 Positive Breast Cancer
A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer
It is a multicenter, open-label, two stage phase II trial, to assess activity, safety and potential early predictors of response in neoadjuvant setting.
- Trial name
- met-HEReMYTA (NCT02488564)
- Testing
- Liposomal doxorubicin, Docetaxel, Trastuzumab
- Where
- 9 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00499681
- Testing
- lapatinib ditosylate, letrozole
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Triple Negative Breast Cancer
Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC
Previous studies have shown that TNBC is sensitive to DNA crosslinking-related chemotherapeutic drugs such as platinum. However, there is a lack of large sample prospective clinical data to compare the efficacy of TP and EC-T /…
- Trial name
- NCT04664972
- Testing
- Docetaxel +doxorubicin+ cyclophosphamide, Docetaxel +Cisplatin
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Adjuvant Post-Tamoxifen Exemestane Trial
The ATENA phase III randomized parallel-group multicenter trial is designed to compare 5 years of adjuvant exemestane versus 5 years of observation in postmenopausal women with operable breast cancer who have received 5-7 years…
- Trial name
- ATENA (NCT00810706)
- Testing
- exemestane
- Where
- Greece
- Volunteers
- 448 people
- Sponsor
- Hellenic Breast Surgeons Society
Breast Cancer
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer
This is a phase II, single institutional study, to evaluate a novel neo-adjuvant regimen in patients with operable, HER2-negative, breast cancer.
- Trial name
- NCT02215876
- Testing
- Doxorubicin, Cyclophosphamide, Eribulin
- Where
- Singapore
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2 Negative Breast Cancer Not Immediately Operated
Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)
Women aged 70 years or older, newly diagnosed for locally advanced unilateral breast cancer, with a histological diagnosis of invasive mammary carcinoma, positive hormone receptors, HER2 status Negative, not immediately operable…
- Trial name
- CALHYS (NCT05664893)
- Testing
- Ribociclib Oral Tablet
- Where
- France
- Sponsor
- Centre Antoine Lacassagne
Breast Cancer, Capecitabine
Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
A Multi-center, III Phase,Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
- Conditions
- Breast Cancer, Capecitabine, Triple Negative Breast Cancer
- Trial name
- MACRO (NCT02012634)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Xijing Hospital
Triple Negative Breast Cancer, Vitamin D Deficiency
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation…
- Conditions
- Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer
- Trial name
- NCT04677816
- Testing
- Standard of Care Neoadjuvant Chemotherapy (NAC), Vitamin D3, Drug Diary
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH
Breast Cancer
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant…
- Trial name
- NCT01966471
- Testing
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab
- Where
- 295 sites in United States, Australia and 34 more
- Volunteers
- 1,846 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer
The primary objective of this study is to compare disease-free survival (DFS) of patients with triple negative breast cancer randomised to treatment with standard adjuvant chemotherapy alone or to standard adjuvant chemotherapy…
- Trial name
- SYSUCC-001 (NCT01112826)
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Sun Yat-sen University